Search Results 1721-1730 of 14738 for anti-TNF drugs

1. Topotecan (Intravenous Route) Precautions - Mayo Clinic

   Male patients who have female partners should use effective birth control during treatment with this medicine and for at least 3 months after the last dose. If ...

2. Pillars and Programs - Center for Individualized Medicine - Mayo Clinic Research

   Additionally, this pillar investigates microorganisms with potential therapeutic benefits, validates strategies for gene therapy and analyzes biological age and ...

3. Difluprednate (Ophthalmic Route) Description and Brand Names - Mayo Clinic

   It is also used to treat an eye condition called endogenous anterior uveitis (eye inflammation). This medicine belongs to the group of medicines known as ...

4. Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma - Mayo Clinic

   Further, these gains have been the result of interventions during the Consolidation (tandem autologous stem cell transplant) and Post-Consolidation (dinutuximab ...

5. Study of RP-3500 With Niraparib or Olaparib in Advanced Solid Tumors - Mayo Clinic

   Drugs & Supplements A-Z · Health Books · Healthy ... By condition, treatment or drug name. Search tips ... anti-tumor activity. Participation eligibility.

6. A Study to Evaluate Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Patients - Mayo Clinic

   About this study. The purpose of this study is to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability ...

7. Daratumumab And Hyaluronidase-Fihj (Subcutaneous Route) Description and Brand Names - Mayo Clinic

   Drugs and Supplements · Daratumumab And Hyaluronidase-Fihj (Subcutaneous Route) ... treatment) multiple myeloma in patients who have received at least 1 previous ...

8. Nilotinib (Oral Route) Description and Brand Names - Mayo Clinic

   Nilotinib belongs to the general group of medicines known as antineoplastics or cancer medicines. It interferes with the growth of cancer cells, ...

9. A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis - Mayo Clinic

   Participation eligibility · Any anti-CD20 therapy such as rituximab, ocrelizumab, or ofatumumab less than 9 months prior to screening or during screening; · If an ...

10. Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) - Mayo Clinic

    antidiabetic drugs, change in anti-diabetic therapy must follow these requirements: no qualitative change 6 months prior to diagnostic liver biopsy up to ...